The stock market has had an incredible week, with the main indexes closing at their ATHs four times. On Friday, the major indexes updated their record highs after US Fed Chairman Jerome Powell calmed fears over the schedule of tapering the bond-buying program, as some economists anticipated that the central bank would reverse the ultra-easy monetary policy earlier than anticipated.Mike Zigmont, head of research and trading at Harvest Volatility Management, told Reuters:
“I see two things happening. I see a reflexive dip-buying validation and I see the market embracing a dovish Fed.”
While Powell was vague on the timeline, his remarks were interpreted as dovish.Zigmont added:
“The market is very happy that the Fed is pumping more liquidity into the economy every month. The Fed is enabling asset prices to climb and the market is pleased with that.”
While the Fed is pumping money, investing in stocks, especially penny stocks that show high return potential, is the best way to make your cash work for you.
OTC MARKETS THE PLACE TO BE
There are many good OTC stocks that can boost your portfolio’s value in the long term. For investors, we preach the key to trading hot OTC stocks is finding momentum BEFORE it happens and then be patient.We alert our subscribers with our best ideas before our regular readers. This is the value of having a subscription to Insider Financial, which you can sign up for here.If you watch the Insider Financial YouTube channel, you can get a sense of the ideal time to book profits. We warned our subscribers not to get greedy or get caught up in the diamond hands/paper hands BS.[embed]https://www.youtube.com/watch?v=Tv3Is3t2Ae8[/embed]We also recommend you own a portfolio of OTC stocks. For some, that can be as many as 10 to 20 or more OTC stocks. This provides diversification and allows one to manage the market’s moods much easier. It also helps to own shares in the following 4 trending OTC stocks gaining momentum.In this article, we look at 4 top penny stocks on the rise that will greatly reward patient investors. They are Life Clips, Inc (OTCPK: LCLP), Regen BioPharma, Inc (OTCPK: RGBPP), Todos Medical Ltd (OTCQB: TOMDF), and Zomedica Corp (NYSE American: ZOM). Top Penny Stocks #1 LCLP Top Penny Stocks #2 RGBPP Top Penny Stocks #3 TOMDF Top Penny Stocks #4 ZOM
Top Penny Stocks #1 LCLP
Life Clips, Inc is one of the many booming stocks that we manage to spot BEFORE they thrive by looking into their fundamentals as well as other factors. The share price of this Pink Current company has surged by over 100% since Monday, from $0.024 to the current level of $0.057. On Friday, LCLP hit the highest level since 2016 at $0.072.We covered this penny stock in mid-April when it was trading at less than one cent, and analyzed it again in a dedicated article after the company announced it was ready to jump on the crypto bandwagon.While the company operates an AI-powered mental health analytics platform called Cognitive Apps Software Solution, the latest price surge has to do with its crypto business. Specifically, LCLP announced on Thursday that it had completed the acquisition of Belfrics Holdings Limited and its related entities operating cryptocurrency exchanges and blockchain development services in Asia and Africa. Belfrics CEO and Founder, Praveen Kumar, will hold his position as the CEO of Belfrics, while Robert Grinberg will continue to serve as CEO of Life Clips.Grinberg said:
“We believe this acquisition represents a tremendous opportunity for our shareholders. As a result of our great working relationship with the Belfrics team, we were able to close ahead of schedule and discuss many new opportunities.”
As explained more in detail in our dedicated article, Belfrics operates a digital exchange platform, which was fully developed in-house and is supported by the proprietary technology of Belrium Blockchain KYC solution. With 10 operational offices in 8 countries, Belfrics provides localized and personalized support to digital currency traders. Through its Blockchain Academy, Belfrics provides continuous training to traders, developers and blockchain enthusiasts in more than 20 countries. Belfrics is licensed and regulated by the Labuan Financial Services Authority (LFSA) in Malaysia.LCLP issued the Belfrics shareholders a new class of preferred stock with an initial issuance price of $20 million in the aggregate. The Belfrics shareholders can earn up to an additional $15 million by reaching certain milestones. This approach is great because it motivates the subsidiary to grow faster.The only issue is that the number of authorized shares of 5 billion might be a bit high for the outstanding shares at 1.57 billion, although we hope the company will continue to be transparent and fair when it comes to its share structure.We believe LCLP can easily grow by several times in the coming months, as it taps into the fastest-growing industry and leverages one of the most regulated crypto exchanges. On top of that, Belfrics said last week that it would launch leveraged forex instruments and crypto derivative contracts starting in September 2021.https://twitter.com/Supergarvis/status/1431002639261741065?s=20
Top Penny Stocks #2 RGBPP
We keep advocating Regen BioPharma, Inc. and for very good reasons – this biotech firm can monetize tons of patents. On this occasion, we want to highlight the preferred stock of the company, which has skyrocketed. RGBP is the ticker for the company’s common stock while RGBPP represents the preferred stock, which is another way to get exposure to the biotech firm. The main difference between the two is the share structure.https://twitter.com/Onside_trap/status/1380793630265315330While RGBPP holders don’t have voting rights as common shareholders do, they get the first claim on the company’s income and assets, that’s why the demand for preferred stocks is higher compared to the common stock, especially from institutions.During the last few days, both tickers have flashed green, but RGBPP has performed better. It surged over 260% since Monday and over 400% since the beginning of the month. RGBPP is now up 2,600% since February and up over 10,000% since the beginning of the year.The last time when we discussed the preferred stock of Regen was in mid-May, when the penny stock was trading at only five cents.Recently, Regen finally got the Pink Current status after sharing its financial reports.https://twitter.com/bbrous11/status/1431521002295644163RGBP is focused on immunology and immunotherapy. It develops small molecule therapies for treating cancer and autoimmune disorders. On top of that, Regen is working on translational medicine platforms for the commercialization of stem cell therapies. The company produces stem-based medicines for diabetes, heart-related illness, circulatory issues, and Chronic Obstructive Pulmonary Disease. The stem cell industry is expected to exceed $15 billion by 2027.Earlier in 2021, the company signed two deals with Oncology Pharma, which rose over 4,000% year-to-date. One deal focuses on treating pancreatic cancer, and the other one is for the treatment of colon cancer. The deal with Oncology has already contributed to Regen’s surging revenue.https://twitter.com/PerfectSpike/status/1431344749194084361Despite the price spike, Regen is still undervalued and has a lot of potential. When it gets acquired at some point by a larger company, you better own both RGBP and RGBPP.
Top Penny Stocks #3 TOMDF
Todos Medical Ltd has been bullish in August, gaining over 100% during the last five days and almost 40% since the beginning of the month. The penny stock is now trading at $0.042, after breaking above five cents on Tuesday and touching the highest level since the end of April.Todos is an in vitro diagnostics company focused on the distribution of a comprehensive suite of solutions for the screening and diagnosis of COVID-19 and the development of blood tests for the early detection of cancer and Alzheimer's disease.Obviously, given the current situation, a lot of emphasis is put on everything related to COVID-19. Todos not only provides all kinds of COVID testing solutions, such as kits for molecular tests, antigen tests, and machines and reagents for RNA extraction, it also has a COVID drug candidate that is currently in Phase 2 of testing in Israel. If you think that the current vaccines will reduce the need for treatments, you should consider the new variants. Last month, Israel said that Pfizer, which recently got the full approval from the US FDA, was only 39% effective against the Delta variant. If Todos succeeds with its drug candidate, it will likely explode.The drug candidate is a more concentrated version of Tollovid (a dietary supplement for the immune system) for COVID-19 infected patients. It uses a proprietary blend of botanical extracts with an active chemical ingredient that limits replication of coronaviruses by using a protease inhibitor. https://todosmedical.com/tollovid?hsLang=enTodos also has a unique COVID testing approach that measures the 3CL protease from upper respiratory samples, which can be more accurate than the standard PCR testing used worldwide, although it provides PCR tests as well.On August 26, TOMDF announced that its CLIA/CAP certified lab Provista Diagnostics had successfully completed the validation studies required to put the Kogene Biotech PCR Variant Test Kit into production and expects to launch variant testing in September this year. The Kogene Variant Kit is a PCR kit capable of identifying the key mutations associated with specific SARS-CoV-2 variants, including the key P681R mutation identified in the Delta variant, which allows Todos to categorize the lineage of the strain responsible for a positive test result. The test can be completed in as little as one hour, significantly faster than genome sequencing, and is highly scalable with the Tecan liquid handling automation currently onsite at Provista.https://twitter.com/todosmedical/status/1430917079658545165The $30 million Israeli company is trading on the OTCQB market has other great products that relate to cancer and Alzheimer’s. We think TOMDF is extremely undervalued at this point. For more info on TOMDF, you can read what biotech analyst Chris Sandburg had to say here.
Top Penny Stocks #4 ZOM
Zomedica Corp is the largest company of today’s list, having a market cap of $615 million. The penny stock is traded on the NYSE American exchange, which is designed for growing small caps. ZOM has gained over 30% during the last five days, although it is trading at the same level where it started the month. On Friday, you had to pay $0.63 per share.The penny stock has actually been in bearish mood since February when it found strong resistance at $2.90, which remains the highest level year-to-date. However, the January-February rally, when the penny stock exploded from 30 cents to almost $3, has more to do with investors considering ZOM an ideal short squeeze candidate.Zomedica is a veterinary health company creating products for dogs and cats by focusing on the unmet needs of clinical veterinarians. Zomedica's product portfolio will include innovative diagnostics and medical devices that emphasize patient health and practice health. It is Zomedica's mission to provide veterinarians the opportunity to increase productivity and grow revenue while better serving the animals in their care.The company engages in the development and commercialization of TRUFORMA, a diagnostic biosensor platform for the detection of thyroid disorders in dogs and cats, and adrenal disorders in dogs. It has collaboration agreements with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals, as wlel as with Seraph Biosciences, Inc. for development and commercialization of novel pathogen detection system.Earlier this month, the company released its Q2 data, reporting a net loss of $4.7 million or $.005 per share, compared to a net loss of approximately $5.3 million, or $0.02 per share, for the same period in 2020. Revenue for the three and six months ended June 30, 2021 was $15,693 and $29,817, respectively, and resulted from the sale of our TRUFORMA products and associated warranties. ZOM started the commercialization of TRUFORMA on March 15, 2021 and, accordingly, had only limited sales activity in the first and second quarters of 2021.The company believes that market acceptance of TRUFORMA has been adversely impacted by delays in the development of its fT4 and ACTH assays by the development partner. The fT4 assay will be available for commercial sale in the fall of 2021 and that the ACTH assay will be available for commercial sale by the end of 2021. In total, TRUFORMA is intended to have five initial assays to test for adrenal and thyroid disorders, which will be followed by many more assays to address other disease states. Three of the initial assays (TSH, tT4 and Cortisol) are already available.Once TRUFORMA gets fully commercialized, ZOM will turn into something big. This is a penny stock to hold in the long term, potentially anticipating a big M&A deal. Also, institutional investors show more interest in ZOM.https://twitter.com/DackJorsey7/status/1429453451516387339
THE FINAL NOTE
All of the 4 OTC stocks discussed today are on the rise and are good stocks to hold. Nevertheless, our best advice is to be patient and enter the market during corrections. Buying dips and selling rips as swing trades remains the best strategy in the penny stock market. Still, whenever an OTC stock is in the middle of a bull run, we recommend our subscribers to book profits.It’s very important to eye OTC stocks that have room for growth and have yet to make their explosive move. There are plenty of opportunities, and we take our time to monitor hundreds of penny stocks to buy each week, trying to find the best alerts for our subscribers.Remember, all you need is one or two OTC stocks to succeed in order to crush the market averages.As always, good luck to all (except the shorts)!
WHEN INSIDER FINANCIAL HAS A STOCK ALERT, IT CAN PAY TO LISTEN. AFTER ALL, OUR FREE NEWSLETTER HAS FOUND MANY TRIPLE-DIGIT WINNERS FOR OUR SUBSCRIBERS. WE SPECIALIZE IN FINDING MOMENTUM BEFORE IT HAPPENS!
Disclosure: We have no position in any of the securities mentioned. We wrote this article ourselves and it expresses our own opinions. We are not receiving compensation for it. We have no business relationship with any company whose stock is mentioned in this article. Insider Financial is not an investment advisor and does not provide investment advice. Always do your own research and make your own investment decisions. This article is not a solicitation or recommendation to buy, sell, or hold securities. This article is meant for informational and educational purposes only and does not provide investment advice.
Discover Hidden Gems
Don't miss the next big opportunity. Subscribe for timely alerts on potential market movers.
